Population pharmacokinetics of rezafungin in patients with fungal infections

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

Bergstrand, M., Hooker, A. C., Wallin, J. E., & Karlsson, M. O. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9255-z · Cited by 1,435 · see citing works

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

Ashbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 721 · see citing works

A Bayesian Extension of the Minimum AIC Procedure of Autoregressive Model Fitting

Akaike, H. (1979) · Biometrika · doi:10.1093/biomet/66.2.237 · Cited by 629 · see citing works

Man versus Beast: Pharmacokinetic Scaling in Mammals

Mordenti, J. J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 391 · see citing works

Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE Trial

Thompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1380 · Cited by 163 · see citing works

Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults

Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · see citing works

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

Sinnollareddy, M., Roberts, J. A., Lipman, J., Akova, M., Bassetti, M., Waele, J. J. D., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0758-3 · Cited by 147 · see citing works

Antifungal Pharmacokinetics and Pharmacodynamics

Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134 · see citing works

Allometric size: The scientific theory and extension to normal fat mass

Holford, N. H. G., & Anderson, B. J. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.056 · Cited by 132 · see citing works

Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients

John, J., Loo, A. S., Mazur, S., & Walsh, T. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1671971 · Cited by 107 · see citing works

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species

Ong, V. S., James, K. D., Smith, S. M., & Krishnan, B. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01626-16 · Cited by 52 · see citing works

We can do better: a fresh look at echinocandin dosing

Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx448 · Cited by 46 · see citing works

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy

Miesel, L., Lin, K., & Ong, V. S. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.546 · Cited by 46 · see citing works

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V. S., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 44 · see citing works

Overview of antifungal dosing in invasive candidiasis

Pea, F., & Lewis, R. E. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx447 · Cited by 42 · see citing works

Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve

Baron, K. T., & Gastonguay, M. R. (2015) · Cited by 40 · see citing works

Between-subject variability: should high be the new normal?

Al-Sallami, H. S., Cheah, S. L., Han, S. Y., Liew, J., Lim, J., Ng, M. A., Solanki, H., Soo, R. J., Tan, V. S. Y., & Duffull, S. B. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1740-8 · Cited by 39 · see citing works

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Lakota, E. A., Ong, V. S., Flanagan, S., & Rubino, C. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02603-17 · Cited by 39 · see citing works

mrgsolve: Simulate from ODE-Based Models

Baron, K. T. (2017) · doi:10.32614/cran.package.mrgsolve · Cited by 23 · see citing works

We can do better: a fresh look at echinocandin dosing

Bader, J. C., Bhavnani, S. M., Andes, D. R., & Ambrose, P. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky013 · Cited by 13 · see citing works

CD101 Prophylactic Dose Rationale for Prevention of Aspergillus, Candida, and Pneumocystis Infections

Flanagan, S. D., Sandison, T., Locke, J. B., Ong, V. S., Ye, G., Bartizal, K. F., & Daruwala, P. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.484 · Cited by 6 · see citing works

Emerging Candida glabrata Resistance and Echinocandin Dosing: A Call to Arms!

Bader, J. C., Lakota, E. A., Bhavnani, S. M., & Ambrose, P. G. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw172.1521 · Cited by 4 · see citing works

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192 · see citing works

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials

Thompson, G. R., Soriano, À., Honoré, P. M., Bassetti, M., Cornely, O. A., Kollef, M. H., Kullberg, B. J., Pullman, J. R., Hites, M., Fortün, J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00551-0 · Cited by 83 · see citing works

Rezafungin: First Approval

Syed, Y. Y. (2023) · Drugs · doi:10.1007/s40265-023-01891-8 · Cited by 66 · see citing works

Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)

Carvalhaes, C. G., Klauer, A. L., Rhomberg, P. R., Pfaller, M. A., & Castanheira, M. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.02449-21 · Cited by 40 · see citing works

The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics

Andes, D. R., Brüggemann, R. J. M., Flanagan, S., Lepak, A. J., Lewis, R. E., Ong, V. S., Rubino, C. M., & Sandison, T. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae415 · Cited by 26 · see citing works

Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis

Roepcke, S., Passarell, J. A., Walker, H., & Flanagan, S. D. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00916-23 · Cited by 25 · see citing works

Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis

Novy, E., Roger, C., Roberts, J. A., & Cotta, M. O. (2023) · Critical Care · doi:10.1186/s13054-023-04742-w · Cited by 21 · see citing works

Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations

Albanell‐Fernández, M. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01461-5 · Cited by 19 · see citing works

Rezafungin in special populations with candidaemia and/or invasive candidiasis

Cornely, O. A., Dupont, H., Mikulska, M., Rautemaa‐Richardson, R., García‐Vidal, C., Thompson, G. R., & Hoenigl, M. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106435 · Cited by 19 · see citing works

Current Antifungals and the Developing Pipeline

Johnson, M. D., & Moore, W. J. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.01.001 · Cited by 11 · see citing works

An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis

Sharma, D., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2331775 · Cited by 11 · see citing works

Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects

Flanagan, S. D., Ong, V. S., Marbury, T. C., Jandourek, A., Gandhi, R. G., & Sandison, T. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2943 · Cited by 9 · see citing works

Therapeutic Approaches for Combating Aspergillus Associated Infection

Chhillar, A. K., Punia, A., Choudhary, P., Sharma, N., Dahiya, S., & Gulia, P. (2022) · Current Drug Targets · doi:10.2174/1389450123666220623164548 · Cited by 7 · see citing works

Spectrum and management of rare Candida /yeast infections in Kuwait in the Middle East

Ahmad, S., Asadzadeh, M., Al‐Sweih, N., & Khan, Z. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241263733 · Cited by 5 · see citing works

Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension Study

Thompson, G. R., Huang, H., Feng, S., Yu, Y., Soriano, À., Cornely, O. A., Kullberg, B. J., Pappas, P. G., Kollef, M. H., Vázquez, J. A., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf555 · Cited by 4 · see citing works

Formulary Drug Review: Rezafungin

Kessel, B., & Baker, D. E. (2023) · Hospital Pharmacy · doi:10.1177/00185787231206523 · Cited by 2 · see citing works

Antifongiques

Aguilar, C., Serris, A., Paccoud, O., Jullien, V., Alanio, A., Frange, P., Lanternier, F., & Lortholary, O. (2026) · EMC-Maladies infectieuses/Encyclopédie médico-chirurgicale. Maladies infectieuses · doi:10.1016/s1166-8598(25)45573-2 · Cited by 1 · see citing works

Development of a rezafungin isolate verification panel and comparison of reference method to ThermoFisher Sensititre YeastOne panel MIC results

DiFranco-Fisher, J. M., & Koeth, L. M. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.117100

Rezafungin: A β-(1,3)-D-glucan synthase inhibitor as antifungal drug derived from Echinocandin B0

Luo, H., Zang, Y., & Zhang, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00014-7

Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient

Fernández-Fernández, R., García-Martínez, R., Sánchez-Yebra, W., Chueca, N., & Colmenero, M. (2026) · Microorganisms · doi:10.3390/microorganisms14030683

Interactions hôte-candida au cours des péritonites fongiques graves de réanimation

Novy, E. (2024) · doi:10.70675/bb875beazbffcz45cdz85b2z2ac1b68c7226

Is there a role for rezafungin in intra-abdominal Candida spp. infections? A case series and literature review

Diella, L., Bavaro, D. F., Gazzola, P., Roperti, M., Verduci, C., Mondatore, D., Morelli, P., Bussini, L., Vanoni, M., Fusilli, N., et al. (2026) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2026.101641

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Lakota, E. A., Ong, V. S., Flanagan, S., & Rubino, C. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02603-17 · Cited by 39 · see citing works

Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis

Roepcke, S., Passarell, J. A., Walker, H., & Flanagan, S. D. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00916-23 · Cited by 25 · see citing works

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

Lakota, E. A., Ganesan, H., Flanagan, S., Ong, V. S., Sandison, T., Bhavnani, S. M., Rubino, C. M., & Ambrose, P. G. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.1221 · Cited by 1 · see citing works

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy

Miesel, L., Lin, K., & Ong, V. S. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.546 · Cited by 46 · see citing works

Pharmacokinetic-Pharmacodynamic Analyses of Dose Selection for Rezafungin Prophylaxis Against Invasive Fungal Infections in Bone Marrow Transplantation

Brown, J. W., Lakota, E. A., Flanagan, S., Sandison, T., Ong, V. S., & Rubino, C. M. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.581 · Cited by 3 · see citing works